137 related articles for article (PubMed ID: 12194942)
1. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
Borlak J; Thum T
Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
[No Abstract] [Full Text] [Related]
2. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
3. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
Thijssen HH; Verkooijen IW; Frank HL
Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
[No Abstract] [Full Text] [Related]
4. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
[TBL] [Abstract][Full Text] [Related]
7. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
11. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
Inoue K; Yamazaki H; Shimada T
Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of CYP2C subfamily in a Japanese population.
Ieiri I; Higuchi S
J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
[No Abstract] [Full Text] [Related]
14. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
15. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
[TBL] [Abstract][Full Text] [Related]
18. Phenytoin intoxication induced by fluvoxamine.
Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
Goldstein JA
Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
[No Abstract] [Full Text] [Related]
20. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
Nasu K; Kubota T; Ishizaki T
Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
